Literature DB >> 9713307

Tumour grade does not change between primary and recurrent mammary carcinoma.

R R Millis1, D M Barnes, O T Lampejo, M K Egan, P Smith.   

Abstract

The primary tumour grade in 115 patients with infiltrating ductal carcinoma of the breast was compared with the type of the ductal carcinoma in situ (DCIS) component and with the grade of 169 locally recurrent and metastatic lesions. 102 patients had axillary lymph node metastases at the time of primary surgery, 49 had subsequent recurrences and 36 had both. There was concordance of grade between the primary tumour and axillary lymph node metastases and with subsequent locally recurrent and metastatic lesions. The type of the DCIS component was also significantly associated with the grade of the infiltrating component. No evidence of progression of tumour grade between these phases of mammary carcinoma was found.

Entities:  

Mesh:

Year:  1998        PMID: 9713307     DOI: 10.1016/s0959-8049(97)10072-7

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Tumour histological grade may progress between primary and recurrent invasive mammary carcinoma.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2002-04       Impact factor: 3.411

Review 2.  Is DCIS breast cancer, and how do I treat it?

Authors:  N Bijker; M Donker; J Wesseling; G J den Heeten; E J Th Rutgers
Journal:  Curr Treat Options Oncol       Date:  2013-03

3.  A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH.

Authors:  R Roylance; P Gorman; T Papior; Y-L Wan; M Ives; J E Watson; C Collins; N Wortham; C Langford; H Fiegler; N Carter; C Gillett; P Sasieni; S Pinder; A Hanby; I Tomlinson
Journal:  Oncogene       Date:  2006-05-15       Impact factor: 9.867

4.  Genomic heterogeneity of breast tumor pathogenesis.

Authors:  Rachel E Ellsworth; Jeffrey A Hooke; Craig D Shriver; Darrell L Ellsworth
Journal:  Clin Med Oncol       Date:  2009-07-29

5.  A comparison of clinicopathological features and molecular markers in british and nigerian women with breast cancer.

Authors:  Isaac D Gukas; Anne C Girling; Barnabas M Mandong; Wendy Prime; Barbara A Jennings; Samuel J Leinster
Journal:  Clin Med Oncol       Date:  2008-04-24

6.  Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.

Authors:  N Bijker; J L Peterse; L Duchateau; E C Robanus-Maandag; C A Bosch; C Duval; S Pilotti; M J van de Vijver
Journal:  Br J Cancer       Date:  2001-02       Impact factor: 7.640

7.  Are ipsilateral breast tumour invasive recurrences in young (< or =40 years) women more aggressive than their primary tumours?

Authors:  B Sigal-Zafrani; M A Bollet; G Antoni; A Savignoni; A Vincent-Salomon; J-Y Pierga; R Salmon; X Sastre-Garau; A Fourquet
Journal:  Br J Cancer       Date:  2007-09-18       Impact factor: 7.640

8.  Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast.

Authors:  R R Millis; S E Pinder; K Ryder; R Howitt; S R Lakhani
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

9.  Deciphering a subgroup of breast carcinomas with putative progression of grade during carcinogenesis revealed by comparative genomic hybridisation (CGH) and immunohistochemistry.

Authors:  E Korsching; J Packeisen; M W Helms; C Kersting; R Voss; P J van Diest; B Brandt; E van der Wall; W Boecker; H Bürger
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.